Genmab Upbeat About Advancing Acasunlimab As BioNTech Exits

Analysts are split on the future for acasunlimab after the German biotech pulled out of co-development but Genmab is all set to kick off a Phase III trial in metastatic non-small-cell lung cancer for the bispecific antibody which acts on 4-1BB, a receptor expressed on activated T cells and natural killer cells.

Jan van de Winkel
Jan van de Winkel • Source: Genmab

Genmab A/S's ability to drive compounds through late-stage trials on its own will be put to the test following the news that BioNTech SE has pulled out of a pact to further co-develop acasunlimab for lung cancer.

More from Anticancer

More from Therapy Areas